ATE550440T1 - Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung - Google Patents

Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung

Info

Publication number
ATE550440T1
ATE550440T1 AT05821698T AT05821698T ATE550440T1 AT E550440 T1 ATE550440 T1 AT E550440T1 AT 05821698 T AT05821698 T AT 05821698T AT 05821698 T AT05821698 T AT 05821698T AT E550440 T1 ATE550440 T1 AT E550440T1
Authority
AT
Austria
Prior art keywords
breast cancer
prediction
molecular indicators
treatment response
likelihood
Prior art date
Application number
AT05821698T
Other languages
English (en)
Inventor
Joffre Baker
John Bryant
Soonmyung Paik
Steven Shak
Original Assignee
Genomic Health Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc, Nsabp Foundation Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of ATE550440T1 publication Critical patent/ATE550440T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
AT05821698T 2004-11-05 2005-11-04 Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung ATE550440T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62544204P 2004-11-05 2004-11-05
PCT/US2005/039970 WO2006052731A2 (en) 2004-11-05 2005-11-04 Molecular indicators of breast cancer prognosis and prediction of treatment response

Publications (1)

Publication Number Publication Date
ATE550440T1 true ATE550440T1 (de) 2012-04-15

Family

ID=36337021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05821698T ATE550440T1 (de) 2004-11-05 2005-11-04 Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung

Country Status (10)

Country Link
US (2) US7622251B2 (de)
EP (1) EP1815014B1 (de)
JP (1) JP4939425B2 (de)
AT (1) ATE550440T1 (de)
AU (1) AU2005304878B2 (de)
CA (1) CA2585561C (de)
DK (1) DK1815014T3 (de)
ES (1) ES2384107T3 (de)
IL (1) IL182930A (de)
WO (1) WO2006052731A2 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3115470T3 (en) * 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
EP1737980A2 (de) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Genexpressionsmarker zur vorhersage des ansprechens auf chemotherapie
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1824340A4 (de) * 2004-12-17 2009-08-05 Bionovo Inc Verfahren zur verwendung von extrakten von epimediumspezies
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
EP1873258A1 (de) 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Nachweis von ESR1 Amplifikation im Brustkrebs
ES2405654T3 (es) * 2006-09-21 2013-05-31 Nuclea Biomarkers Llc Perfiles de expresión asociados con el tratamiento con irinotecan
WO2008037700A2 (en) * 2006-09-27 2008-04-03 Siemens Healthcare Diagnostics Gmbh Methods for breast cancer prognosis
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
EP2090588A4 (de) 2006-10-23 2010-04-07 Neocodex S L In-vitro-verfahren zur prognose und/oder diagnose von überempfindlichkeit gegen estrogene oder substanzen mit estrogener wirkung
US8470534B2 (en) * 2006-12-01 2013-06-25 Erik S. Knudsen Methods of predicting resistance or sensitivity to therapies for cancer
WO2008115561A2 (en) * 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1978106A1 (de) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Nachweis einer ESR1-Amplifikation bei Endometriumkrebs und Ovarialkrebs
US20090070138A1 (en) * 2007-05-15 2009-03-12 Jason Langheier Integrated clinical risk assessment system
CA2688049A1 (en) * 2007-05-31 2008-12-04 Dako Denmark A/S Methods for utilizing esr copy number changes in breast cancer treatments and prognoses
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
US8092841B2 (en) * 2007-08-08 2012-01-10 Bionovo, Inc. Estrogenic extracts of Ligustrum lucidum ait. of the oleaceae family and uses thereof
WO2009026128A2 (en) * 2007-08-16 2009-02-26 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
CA2698152C (en) * 2007-09-05 2018-08-14 Laurentian University Method of using tumour rna integrity to measure response to chemotherapy in cancer patients
WO2009033075A1 (en) * 2007-09-07 2009-03-12 Bionovo. Inc. ESTROGENIC EXTRACTS OF Scuttelaria barbata D. DON OF THE LABIATAE FAMILY AND USES THEREOF
US20090068298A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
WO2009033025A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of asparagus conchinchinensis (lour.) merr of the liliaceae family and uses thereof
AU2008296076A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. Estrogenic extracts of Pueraria lobata Willd, Ohwi of the Leguminosae family and uses thereof
CA2706330A1 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata d. don
AU2008326426A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Methods of detecting and treatment of cancers using scuttelaria barbata extract
CA2706326A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
WO2009067553A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
EP2065474A1 (de) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH Verfahren für die Prognose der Therapiereaktion zur endokrinen Behandlung
EP2065473A1 (de) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH Verfahren zur Prognosebeurteilung und Vorhersage des Behandlungserfolgs von gynäkologischem Krebs
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
WO2009095319A1 (de) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
CA2721191A1 (en) * 2008-04-14 2009-10-22 Bionovo, Inc. Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
US20090270273A1 (en) * 2008-04-21 2009-10-29 Complete Genomics, Inc. Array structures for nucleic acid detection
JP2011519947A (ja) * 2008-05-06 2011-07-14 バイオノボ・インコーポレーテッド 膣および外陰の委縮を治療するために使用するエストロゲン様抽出物
WO2009149411A2 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositons
JP2011522822A (ja) * 2008-06-06 2011-08-04 バイオノボ・インコーポレーテッド エストロゲン受容体β媒介性病状の治療のためのダイオウ（Ｒｈｅｕｍｐａｌｍａｔｕｍ）由来のアントラキノンおよび類似体
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US20100069481A1 (en) * 2008-09-03 2010-03-18 Bionovo, Inc. Methods and compositions for the treatment of cancer
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP5550060B2 (ja) * 2008-10-03 2014-07-16 独立行政法人産業技術総合研究所 そうか病病原菌種のｐｃｒ定量用試薬キット
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010045234A1 (en) * 2008-10-14 2010-04-22 University Of Louisville Research Foundation, Inc. Methods of optimizing treatment of estrogen-receptor positive breast cancers
ES2343996B1 (es) 2008-12-11 2011-06-20 Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Metodo para la subclasificacion de tumores.
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
AU2010246233A1 (en) * 2009-04-28 2011-12-22 Bionovo, Inc. Method of reducing fat accumulation and inducing weight loss
EP2425015B1 (de) * 2009-04-29 2018-01-10 Ralph Wirtz Verfahren zur beurteilung der prognose und zur vorhersage eines therapieerfolgs bei krebs anhand der bestimmung von hormonrezeptor-expressionsniveaus
EP2425021A4 (de) * 2009-05-01 2013-03-06 Nuvera Biosciences Inc Index der genomexpression von estrogenrezeptor (er) und er-assozierten genen
EP2253715A1 (de) * 2009-05-14 2010-11-24 RWTH Aachen Neue Targets zur Krebstherapie und/oder -diagnose
PL2553118T3 (pl) 2010-03-31 2015-03-31 Sividon Diagnostics Gmbh Sposób przewidywania nawrotu raka sutka podczas leczenia endokrynologicznego
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
EP2611941A4 (de) 2010-08-30 2014-01-22 Myriad Genetics Inc Gensignaturen zur krebsdiagnose und -prognose
RU2486518C1 (ru) * 2012-01-10 2013-06-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ прогнозирования возникновения местных рецидивов в послеоперационном рубце при уницентрическом инвазивном протоковом раке молочной железы у больных с сохраненной менструальной функцией
BR112014026440A8 (pt) 2012-04-24 2018-01-16 Rna Diagnostics Inc análises, métodos e aparelhos para avaliação de disrupção de rna.
ES2938766T3 (es) 2012-11-16 2023-04-14 Myriad Genetics Inc Firmas génicas para el pronóstico de cáncer
HK1215875A1 (zh) 2012-12-03 2016-09-23 Rna Diagnostics Inc. 用於监视放射治疗癌症反应的方法和试剂盒
EP2951317B1 (de) 2013-02-01 2017-10-11 Sividon Diagnostics GmbH Verfahren zur vorhersage des nutzens von der einbeziehung von taxan in eine chemotherapiekur bei patienten mit brustkrebs
US10731222B2 (en) 2013-10-04 2020-08-04 Rna Diagnostics Inc. RNA disruption assay for predicting survival
EP2910645A1 (de) * 2014-02-25 2015-08-26 STRATIFYER Molecular Pathology GmbH Verfahren und Zusammensetzungen zur Vorhersage der therapeutischen Wirksamkeit von Krebsbehandlungen und Krebsprognose bei Antikörperbehandlung
EP3143160B1 (de) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gensignaturen für krebsprognosen
CN104004844A (zh) * 2014-05-28 2014-08-27 杭州美中疾病基因研究院有限公司 乳腺癌21基因联合检测试剂盒及其制备方法
US11060149B2 (en) 2014-06-18 2021-07-13 Clear Gene, Inc. Methods, compositions, and devices for rapid analysis of biological markers
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
EP3389481A4 (de) 2015-12-18 2019-05-22 Clear Gene, Inc. Verfahren, zusammensetzungen, kits und vorrichtungen zur schnellanalyse von biologischen markern
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
EP3679160A4 (de) 2017-09-08 2021-05-19 Myriad Genetics, Inc. Verfahren zur verwendung von biomarkern und klinischen variablen zur vorhersage des nutzens von chemotherapie.
US12008747B2 (en) * 2019-07-29 2024-06-11 Case Western Reserve University Population-specific prediction of prostate cancer recurrence based on stromal morphology features
CN111500724B (zh) * 2020-04-28 2023-11-21 启程医学科技(山东)有限公司 用于乳腺癌六基因同时检测的引物组与探针组合
WO2023081988A1 (pt) * 2021-11-09 2023-05-19 Coelho Guilherme Portela Método para predição de eficácia de tratamento para câncer de mama

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5962312A (en) 1995-12-18 1999-10-05 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
KR100645448B1 (ko) 1996-11-20 2006-11-13 예일 유니버시티 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
CA2391805A1 (en) 1999-10-06 2001-04-12 The Regents Of The University Of California Differentially expressed genes associated with her-2/neu overexpression
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (de) 2000-01-28 2006-04-05 Althea Technologies Inc Verfahren zur analyse der genexpression
WO2001055309A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
WO2001075159A2 (en) 2000-03-31 2001-10-11 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001280008A1 (en) 2000-07-21 2002-02-05 Global Genomics Ab A method and an algorithm for mRNA expression analysis
AU2001278076A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-5 proteins and related reagents and methods of use thereof
WO2002008260A2 (en) 2000-07-26 2002-01-31 Stanford University Bstp-ecg1 protein and related reagents and methods of use thereof
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
AU2002234799A1 (en) 2000-12-08 2002-06-18 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7097966B2 (en) 2001-01-12 2006-08-29 Yale University Detection of survivin in the biological fluids of cancer patients
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
CA2440703A1 (en) 2001-01-24 2002-08-01 Protein Design Labs, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
EP1373896A2 (de) 2001-03-12 2004-01-02 MonoGen, Inc. Auf zellen basierte nachweis und unterscheidung von krankheitszuständen
DK1410011T3 (da) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnose og prognose for brystcancerpatienter
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US20040009489A1 (en) 2001-09-28 2004-01-15 Golub Todd R. Classification of lung carcinomas using gene expression analysis
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
DK3115470T3 (en) 2002-03-13 2018-11-05 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US20050216961A1 (en) 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
EP1365034A3 (de) 2002-05-21 2004-02-18 Bayer HealthCare AG Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Prävention und Behandlung von malignen Tumoren
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
ES2905579T3 (es) * 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
EP1737980A2 (de) * 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Genexpressionsmarker zur vorhersage des ansprechens auf chemotherapie

Also Published As

Publication number Publication date
WO2006052731A3 (en) 2007-04-19
EP1815014A2 (de) 2007-08-08
EP1815014B1 (de) 2012-03-21
US7622251B2 (en) 2009-11-24
IL182930A0 (en) 2007-09-20
DK1815014T3 (da) 2012-06-18
US20100184041A1 (en) 2010-07-22
JP2008518620A (ja) 2008-06-05
CA2585561A1 (en) 2006-05-18
CA2585561C (en) 2018-07-17
ES2384107T3 (es) 2012-06-29
WO2006052731A2 (en) 2006-05-18
JP4939425B2 (ja) 2012-05-23
IL182930A (en) 2013-03-24
US20060166231A1 (en) 2006-07-27
AU2005304878B2 (en) 2010-07-08
AU2005304878A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
ATE550440T1 (de) Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
Dong et al. Upregulation of long non-coding RNA small nucleolar RNA host gene 12 contributes to cell growth and invasion in cervical cancer by acting as a sponge for MiR-424-5p
Zhou et al. miR424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway
Ahn et al. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients
Xu et al. c-Met and CREB1 are involved in miR-433-mediated inhibition of the epithelial–mesenchymal transition in bladder cancer by regulating Akt/GSK-3β/Snail signaling
Liu et al. Mir-758-5p suppresses glioblastoma proliferation, migration and invasion by targeting ZBTB20
Lu et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression
Yu et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome
Zhang et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis
Lai et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation
Hu et al. Long non-coding RNA BLACAT1 promotes breast cancer cell proliferation and metastasis by miR-150-5p/CCR2
Theisen et al. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma
Chen et al. Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells
Wang et al. Overexpression of MAPT-AS1 is associated with better patient survival in breast cancer
Tian et al. AGAP2‐AS1 serves as an oncogenic lncRNA and prognostic biomarker in glioblastoma multiforme
DE602005023646D1 (de) Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
Ma et al. Downregulation of lncRNA ZEB1-AS1 represses cell proliferation, migration, and invasion through mediating PI3K/AKT/mTOR signaling by miR-342-3p/CUL4B axis in prostate cancer
Wu et al. LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1
Ma et al. TPX2 promotes cell proliferation and migration via PLK1 in OC
Toffoli et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival
Zhu et al. Activation of G-protein-coupled estrogen receptor inhibits the migration of human nonsmall cell lung cancer cells via IKK-β/NF-κB signals
Nie et al. Prognostic significance of long noncoding RNA Z38 as a candidate biomarker in breast cancer
Hou et al. LncRNA OTUD6B-AS1 induces cisplatin resistance in cervical cancer cells through up-regulating cyclin D2 via miR-206
Yu et al. Decreased long non-coding RNA SPRY4-IT1 contributes to ovarian cancer cell metastasis partly via affecting epithelial–mesenchymal transition
Zhao et al. Single-cell RNA-sequencing portraying functional diversity and clinical implications of IFI6 in ovarian cancer